Leerink Partnrs Has Negative Outlook of IDYA FY2026 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Research analysts at Leerink Partnrs decreased their FY2026 earnings per share estimates for IDEAYA Biosciences in a research report issued on Tuesday, September 9th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($4.05) per share for the year, down from their prior estimate of ($3.88). The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences’ FY2027 earnings at ($4.04) EPS.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.03). The company had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $3.48 million. During the same period in the previous year, the business posted ($0.68) EPS. The company’s revenue for the quarter was up NaN% compared to the same quarter last year.

Other analysts have also issued reports about the stock. Citigroup restated a “buy” rating on shares of IDEAYA Biosciences in a research note on Tuesday. Wells Fargo & Company began coverage on shares of IDEAYA Biosciences in a report on Thursday, June 26th. They set an “overweight” rating and a $44.00 price target for the company. Royal Bank Of Canada increased their price objective on shares of IDEAYA Biosciences from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Tuesday. Citizens Jmp assumed coverage on shares of IDEAYA Biosciences in a research report on Thursday, September 4th. They set a “mkt outperform” rating and a $41.00 price objective for the company. Finally, JMP Securities began coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 4th. They set a “market outperform” rating and a $41.00 target price for the company. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $42.75.

IDEAYA Biosciences Price Performance

IDYA stock opened at $24.71 on Thursday. The business’s 50-day moving average is $23.84 and its two-hundred day moving average is $20.70. The firm has a market capitalization of $2.17 billion, a P/E ratio of -6.52 and a beta of 0.12. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $37.80.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of IDYA. CWM LLC grew its position in shares of IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company’s stock valued at $39,000 after buying an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in IDEAYA Biosciences by 180.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock valued at $39,000 after acquiring an additional 1,546 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of IDEAYA Biosciences during the fourth quarter worth about $47,000. Signaturefd LLC grew its holdings in shares of IDEAYA Biosciences by 374.8% during the first quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock worth $47,000 after purchasing an additional 2,271 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of IDEAYA Biosciences during the second quarter worth about $61,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.